Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor and a nonsteroidal anti-inflammatory drug (NSAID). It is used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, acute pain in adults (including musculoskeletal pain), primary dysmenorrhea (menstrual pain), juvenile rheumatoid arthritis in children aged 2 years and older, and to reduce the number of colon and rectal polyps in people with familial adenomatous polyposis. Celecoxib works by selectively inhibiting the COX-2 enzyme involved in prostaglandin synthesis—thereby reducing inflammation and pain while causing less gastrointestinal mucosal damage compared to traditional NSAIDs that inhibit both COX-1 and COX-2. It is administered orally. Common side effects include abdominal discomfort, nausea, diarrhea; serious risks include cardiovascular events such as heart attack or stroke as well as gastrointestinal bleeding[1][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celecoxib.